CD14 and chronic myelomonocytic leukemia: Recently, Selimoglu-Buet et al. demonstrated, in CMML patients, an increase in the fraction of MO1 CD14+/CD16− monocytes (>94% for a specificity of 95.1% and a sensitivity of 90.6%) at the expense of MO2 (CD14+/CD16+) and MO3 (CD14+low/CD16+) cell fractions (11).